June 21st 2023
Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, review recent clinical data and discuss the current state of fertility preservation in premenopausal patients with breast cancer.
June 20th 2023
Experts discuss the evolving treatment landscape in advanced or recurrent endometrial cancer. They review the latest updates in clinical research, highlighting non-chemotherapy approaches and their impact on treatment selection.
Expert oncologists review the current treatment landscape of biliary tract cancers and consider how they would apply data from clinical trials to their own practice.
June 15th 2023
Two expert oncologists review the standard-of-care and unmet needs in the treatment of lower-risk Myelodysplastic Syndromes [MDS]. They discuss emerging data on novel therapies and consider their impact on the treatment landscape for patients with lower-risk MDS.
June 1st 2023
Martin Dietrich, MD, PhD, and Wade Thomas Iams, MD, discuss the role of antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC) and review the various biomarkers for targeted therapy.
May 31st 2023
Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the use of Bruton tyrosine kinase (BTK) inhibitors for the treatment of relapsed/refractory mantle cell lymphoma.
May 26th 2023
Robert L Coleman, MD, FACOG, FACS, and Bradley J Monk, MD, FACOG, FACS, provide insights on treating patients with advanced ovarian cancer and the evolving treatment landscape.
May 22nd 2023
Expert panelists from the UT Southwestern Medical Center review real world patient cases of renal cell carcinoma to illustrate recent clinical data and exhibit how it has been applied at their institution.
May 15th 2023
Experts in oncology center discussion on patient scenarios and share insight on the treatment landscape for patients with HER2+ metastatic breast cancer.
April 17th 2023
Andrew Armstrong, MD, and Matthew Manning, MD, review the profiles of three patients with metastatic castration-resistant prostate cancer (mCRPC) and discuss how they would have approached their treatment, given recent advances in radiotherapy and other options in the field.
March 31st 2023
A panel of skin cancer experts have a comprehensive discussion on advanced cutaneous squamous cell carcinoma and melanoma, and offer insights on the evolving treatment landscape.
March 23rd 2023
Nelson J. Chao, MD, MBA, discusses the treatment of acute and chronic graft-versus-host disease through the lens of two patient profiles.
Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, discuss recent updates in the prophylactic and treatment strategies for acute and chronic graft versus host disease (GVHD).
March 22nd 2023
Expert panelists review current and emerging treatment approaches in myeloproliferative neoplasms, with focused discussion on monitoring, sequencing, and combination therapy strategies using JAK inhibitors in myelofibrosis.
March 17th 2023
Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, discuss the evolving treatment landscape for advanced renal cell carcinoma.
February 21st 2023
Expert perspectives on the evolving treatment paradigm of HER2-expressing breast cancer and how learnings from recent clinical trials are impacting real-world practices.
January 30th 2023
Komal Jhaveri, MD, FACP, and Paolo Tarantino, MD, discuss updates in the treatment of metastatic breast cancer (mBC) from SABCS 2022 and other recent meetings, and how to best incorporate recent data into clinical practice.
January 16th 2023
Expert oncologists discuss the hormone receptor–positive (HR+) breast cancer treatment landscape and their suggested approaches to treating patients in both the early and metastatic disease settings.
December 22nd 2022
An expert panel discusses recent advances in the treatment of Stage I-III NSCLC and their impact on clinical practice.
Expert oncologist Martin Dietrich, MD, PhD, shares his excitement for an upcoming program wherein he and Meghan Mooradian, MD, highlight the evolving role of immunotherapy and biomarker-driven therapy in non-small cell lung cancer.